Her2-Mutated Cancers

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses a session on the development of HER2 targeted therapies for breast cancer at AACR-NCI-EORTC.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the DESTINY-Lung01 study presented at ESMO 2021.

Prominent cancer researcher José Baselga, MD, PhD, FASCO, who served as head of oncology research and development for AstraZeneca, has died at age 61 years, the company announced in a press release.

The FDA granted fast track designation to poziotinib for previously treated patients with non-small cell lung cancer and HER2 exon 20 mutations, according to a press release from the drug’s manufacturer.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, provided a quick rundown of presentations from the Chemotherapy Foundation Symposium that focused on targeted therapy.